We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Glaxo Sells Wellbutrin Rights to Partner Biovail
Glaxo Sells Wellbutrin Rights to Partner Biovail
May 12, 2009
GlaxoSmithKline (GSK) is selling its U.S. rights for the antidepressant Wellbutrin XL to its partner Biovail for $510 million.